108 related articles for article (PubMed ID: 20466672)
1. Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy.
Kelly KJ; Dominguez JH
Nephrol Dial Transplant; 2010 Oct; 25(10):3204-12. PubMed ID: 20466672
[TBL] [Abstract][Full Text] [Related]
2. Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy.
Kelly KJ; Burford JL; Dominguez JH
Am J Physiol Renal Physiol; 2009 Oct; 297(4):F923-31. PubMed ID: 19656916
[TBL] [Abstract][Full Text] [Related]
3. Renal injury induced in alloxan diabetic rats. Role of Mycophenolate Mofetil as therapeutic agent.
Elseweidy MM; Elswefy SE; Ali AE; Shawky M
Pathol Res Pract; 2014 Dec; 210(12):979-84. PubMed ID: 24939145
[TBL] [Abstract][Full Text] [Related]
4. Effects of mycophenolate mofetil on acute ischaemia-reperfusion injury in rats and its consequences in the long term.
Sabbatini M; Uccello F; Serio V; Troncone G; Varone V; Andreucci M; Faga T; Pisani A
Nephrol Dial Transplant; 2010 May; 25(5):1443-50. PubMed ID: 20031930
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes.
Utimura R; Fujihara CK; Mattar AL; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Jan; 63(1):209-16. PubMed ID: 12472785
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat.
Rodríguez-Iturbe B; Quiroz Y; Shahkarami A; Li Z; Vaziri ND
Kidney Int; 2005 Sep; 68(3):1041-7. PubMed ID: 16105034
[TBL] [Abstract][Full Text] [Related]
7. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
8. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil improves renal haemodynamics, microvascular oxygenation, and inflammation in a rat model of supra-renal aortic clamping-mediated renal ischaemia reperfusion injury.
Ergin B; Heger M; Kandil A; Demirci-Tansel C; Ince C
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):294-304. PubMed ID: 27778375
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil attenuates renal ischemia/reperfusion injury.
Ventura CG; Coimbra TM; de Campos SB; de Castro I; Yu L; Seguro AC
J Am Soc Nephrol; 2002 Oct; 13(10):2524-33. PubMed ID: 12239241
[TBL] [Abstract][Full Text] [Related]
11. Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression.
Kim SM; Lee SH; Lee A; Kim DJ; Kim YG; Kim SY; Jeong KH; Lee TW; Ihm CG; Lim SJ; Moon JY
Transl Res; 2015 Oct; 166(4):375-83. PubMed ID: 26001596
[TBL] [Abstract][Full Text] [Related]
12. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy.
Dominguez J; Wu P; Packer CS; Temm C; Kelly KJ
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F670-9. PubMed ID: 17596532
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
[TBL] [Abstract][Full Text] [Related]
14. Renal C3 complement component: feed forward to diabetic kidney disease.
Kelly KJ; Liu Y; Zhang J; Dominguez JH
Am J Nephrol; 2015; 41(1):48-56. PubMed ID: 25662584
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat.
Bloudícková S; Rajnoch J; Lodererová A; Honsová E; Viklický O
Kidney Blood Press Res; 2006; 29(1):60-6. PubMed ID: 16645304
[TBL] [Abstract][Full Text] [Related]
16. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil ameliorates diabetic nephropathy through epithelial mesenchymal transition in rats.
Xiao X; Wang J; Chang X; Zhen J; Zhou G; Hu Z
Mol Med Rep; 2015 Sep; 12(3):4043-4050. PubMed ID: 26080907
[TBL] [Abstract][Full Text] [Related]
18. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats.
Wu X; Zha D; Xiang G; Zhang B; Xiao SY; Jia R
Cytokine; 2006 Dec; 36(5-6):229-36. PubMed ID: 17337203
[TBL] [Abstract][Full Text] [Related]
19. Could mycophenolate mofetil combined with benazapril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats?
Liu WH; Tang NN; Zhang QD
Chin Med J (Engl); 2009 Jan; 122(2):199-204. PubMed ID: 19187647
[TBL] [Abstract][Full Text] [Related]
20. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair.
Jones EA; Shoskes DA
J Urol; 2000 Mar; 163(3):999-1004. PubMed ID: 10688038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
